USPTO serial 79239267
OXURION
Reviewed by CopyMark Law Group
Reg. 5772180Status 709
- Filing date
- Status date
- Registration date
- Jun 11, 2019
- Examiner
- MESSICK, TABITHA LEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with OXURION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Martin W. Schiffmiller
Martin W. Schiffmiller Kirschstein Israel Schiffmiller & Pieroni, P.C.425 Fifth Avenue, Fifth Floor, Suite 501New York, NY 10016-2223UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; diagnostic medical reagents, chemicals preparations and biological materials all the foregoing being in the form of spatially defined arrays and solutions and reagents for medical laboratory use in diagnosting, monitoring, and predicting diseases and for measuring and predicting response to therapy of cardiac and vascular diseases; pharmaceutical preparations for use in the treatment of hypertension, strokes, cardiac diseases and vascular diseases; pharmaceutical substances and medicines for treatment or prevention of eye disorders and diseases and of ophthalmological disorders and diseases; pharmaceutical preparations and substances for the treatment or prevention of diabetes; medicines for treating or preventing diabetes; ophthalmic medicines and surgical fluids, ophthalmic pharmaceutical preparations; pharmaceutical eye drops | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely research and design relating thereto in the field of ophthalmology, in the field of diabetes and in the field of treatment of cardiovascular disease, cardiac disease and vascular disease; industrial analysis of the pharmaceutical preparations of others used for the treatment of ophthalmologic diseases, diabetes and cardiovascular diseases for quality control purposes; research services in the field of ophthalmology, diabetes and cardiovascular diseases; pharmaceutical and biopharmaceutical research and development; biopharmaceutical product evaluation; research in the field of treatment of cardiovascular disease, cardiac disease, and vascular disease; development of new treatments for pathologies in which vascular biology plays a critical role in the field of biopharmaceuticals | SECTION 71 - CANCELLED | — |
| 044 | Medical services; veterinary services; consultancy services, namely, consultancy in the medical, veterinary and pharmaceutical treatment of patients in the fields of ophthalmology, diabetes and cardiovascular diseases; medical services, namely, cardiac and vascular therapeutic, prognostic and diagnostic testing services | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ThromboGenics
- Other trademarks owned by ThromboGenics
- Other trademarks owned by Oxurion NV
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named OXURION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 26, 2026 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 26, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 26, 2025 | C71T | CANCELLED SECTION 71 | — |
| Nov 14, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 11, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 12, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 21, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 21, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 11, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 13, 2019 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jun 11, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 26, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 26, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 23, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 6, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 6, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 15, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 2, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 30, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 30, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 9, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 25, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 25, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 14, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 13, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 13, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 28, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 24, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 23, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |